BioStem Technologies Files S-1 Registration for U.S. IPO
BioStem Technologies, Inc. (File No. 0001658678) filed its Form S-1 registration statement with the SEC on October 2, 2026, initiating its U.S. IPO process on Nasdaq or NYSE. The 11-MB filing marks the formal start of financial disclosure and regulatory review.
51CFO view：CFOs of biotech IPO candidates must lead S-1 financial section drafting: R&D expense capitalization policy, revenue recognition for clinical-stage collaborations, ASC 730/985 compliance, and SOX 404 readiness. FDA-regulated financial reporting experience is non-negotiable.
BioStem Technologies, Inc. (File No. 0001658678) filed its Form S-1 registration statement with the SEC on October 2, 2026, initiating its U.S. IPO process on Nasdaq or NYSE. The 11-MB filing marks the formal start of financial disclosure and regulatory review.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →